0001055726-23-000004.txt : 20230228 0001055726-23-000004.hdr.sgml : 20230228 20230228174024 ACCESSION NUMBER: 0001055726-23-000004 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230226 FILED AS OF DATE: 20230228 DATE AS OF CHANGE: 20230228 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Weiner David B. CENTRAL INDEX KEY: 0001669080 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-14888 FILM NUMBER: 23687787 MAIL ADDRESS: STREET 1: 717 BEACOM LANE CITY: MERION STATION STATE: PA ZIP: 19066-1603 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: INOVIO PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001055726 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 330969592 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 6769 MESA RIDGE RD. CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 8584103134 MAIL ADDRESS: STREET 1: 6769 MESA RIDGE RD. CITY: SAN DIEGO STATE: CA ZIP: 92121 FORMER COMPANY: FORMER CONFORMED NAME: INOVIO BIOMEDICAL CORP DATE OF NAME CHANGE: 20050404 FORMER COMPANY: FORMER CONFORMED NAME: GENETRONICS BIOMEDICAL CORP DATE OF NAME CHANGE: 20011116 FORMER COMPANY: FORMER CONFORMED NAME: GENETRONICS BIOMEDICAL LTD DATE OF NAME CHANGE: 19980213 4 1 wf-form4_167762396172703.xml FORM 4 X0306 4 2023-02-26 0 0001055726 INOVIO PHARMACEUTICALS, INC. INO 0001669080 Weiner David B. 660 W. GERMANTOWN PIKE SUITE 110 PLYMOUTH MEETING PA 19462 1 0 0 0 Common Stock 2023-02-26 4 M 0 11667 A 904292 D Common Stock 2023-02-26 4 M 0 11667 A 915959 D Common Stock 2023-02-27 4 S 0 11668 1.28 D 904291 D Restricted Stock Unit 2023-02-26 4 M 0 11667 0 D Common Stock 11667.0 11666 D Restricted Stock Unit 2023-02-26 4 M 0 11667 0 D Common Stock 11667.0 23333 D Common Stock Option 1.24 2023-02-27 4 A 0 60000 0 A 2023-02-27 2033-02-27 Common Stock 60000.0 60000 D Restricted Stock Unit 2023-02-27 4 A 0 35000 0 A Common Stock 35000.0 35000 D Each restricted stock unit represents a contingent right to receive one share of common stock. On February 26, 2021, the reporting person was granted 35,000 restricted stock units, vesting as follows: 11,667 shares vested on February 26, 2022; 11,667 shares vested on February 26, 2023; and 11,666 shares will vest on February 26, 2024. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Each restricted stock unit represents a contingent right to receive one share of common stock. On February 26, 2022, the reporting person was granted 35,000 restricted stock units, vesting as follows: 11,667 shares vested on February 26, 2023; 11,667 shares will vest on February 26, 2024; and 11,666 shares will vest on February 26, 2025. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 13, 2022. The vesting schedule for the 60,000 options is as follows: 15,000 shares vested on February 27, 2023; 15,000 shares will vest on February 26, 2024; 15,000 shares will vest on February 26, 2025; and 15,000 shares will vest on February 26, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock. On February 27, 2023, the reporting person was granted 35,000 restricted stock units, vesting as follows: 11,667 shares will vest on February 26, 2024; 11,667 shares will vest on February 26, 2025; and 11,666 shares will vest on February 26, 2026. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. /s/ David B. Weiner 2023-02-28